NCT03414034View on ClinicalTrials.gov

Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

August 14, 2018

Primary Completion Date

October 16, 2023

Study Completion Date

October 16, 2023

Conditions
Metastatic Castration-Resistant Prostate Cancer
Interventions
DRUG

Onvansertib

Onvansertib orally

DRUG

Abiraterone

Abiraterone orally

DRUG

Prednisone

Prednisone orally

Trial Locations (3)

02114

Massachusetts General Hospital, Boston

02215

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston

Sponsors

Lead Sponsor

Cardiff Oncology
All Listed Sponsors
lead

Cardiff Oncology

INDUSTRY

NCT03414034 - Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer | Biotech Hunter | Biotech Hunter